Yeah, who needs the Sigma 1 receptor? That mountain of academic articles touting its therapeutic potential across the whole gamut of CNS diseases probably means nothing...orrr...maybe Allergan didn't feel like ponying up the amount that Missling demands for 2-73. And then what are you going to do, tell the press you just bought an also-ran?
I just love that this Heptares-Sosei-Allergan partnership deal, which is a very good one, nevertheless was clearly not sweet enough for Missling.